WO2004099215A1 - ビンカアルカロイドおよびその塩の利用 - Google Patents
ビンカアルカロイドおよびその塩の利用 Download PDFInfo
- Publication number
- WO2004099215A1 WO2004099215A1 PCT/JP2004/006567 JP2004006567W WO2004099215A1 WO 2004099215 A1 WO2004099215 A1 WO 2004099215A1 JP 2004006567 W JP2004006567 W JP 2004006567W WO 2004099215 A1 WO2004099215 A1 WO 2004099215A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- knee
- cells
- acceptable salt
- derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Diabetes is a disease in which the blood sugar level increases due to insufficient or insufficient blood insulin and complications such as neuropathy, visual impairment, and renal impairment. About Japan alone
- type 1 and type 2 diabetes which produce insulin.
- the cells are destroyed by an autoimmune disease and are caused by an absolute insulin deficiency.
- type 2 diabetes is caused by the development of insulin resistance in target tissues such as muscle, fat, and liver, and a decrease in blood insulin level due to a decrease in the function of knee cells. Therefore, it can be said that both type 1 and type 2 diabetes are due to inadequate action of the ⁇ 10 cells.
- insulin injection is used in most cases for type 1 to lower blood glucose. It goes without saying that about four injections a day are painful for the patient.
- Porcine knee cells are expected to be used for regenerative treatment for diabetes because of their easy availability and immunological properties.However, all cell lines have collected a large amount of cells until now. The technology for inducing differentiation into insulin-producing and releasing cells was not known.
- An object of the present invention is to provide an agent capable of inducing production and / or secretion of insulin by non-tumor cells derived from the knee. Disclosure of the invention
- An agent for increasing insulin-producing ability of non-tumor cells derived from the kidney which comprises as an active ingredient binal alroyd or a pharmacologically acceptable salt thereof.
- binal alroyd or a pharmacologically acceptable salt thereof.
- conobuline it is preferable to use conobuline.
- the drug preferably further contains nicotinamide or nicotinamide and hepatocyte growth factor (HGF).
- a drug that increases the ability of non-tumor cells of the knee to secrete insulin comprising a bin power alkaloid or a pharmacologically acceptable salt thereof, and nicotinamide as active ingredients. It is preferable to use conophylline as the bin alkaloid.
- the drug further contains hepatocyte growth factor (HGF).
- the bin alkaloid or its pharmacology A method for increasing insulin-producing ability of a non-tumor cell derived from a kidney, which comprises adding a commercially acceptable salt. It is preferable to use conophylline as the bin power alkaloid.
- conophylline As the bin power alkaloid.
- nicotinamide or nicotinamide and hepatocyte growth factor (HGF) are added to increase the insulin-producing ability of the non-tumor cells derived from the knee.
- ecotinamide or nicotinamide and hepatocyte growth factor (HGF) it is preferable to use conophylline as the bin alkaloid.
- Non-tumor cells derived from the knee which have increased insulin-producing ability according to the method described in 9 above.
- Non-tumor cells derived from the spleen refers to cells derived from the knee of a living individual and having no tumor-forming ability, including cells collected from the knee of a living individual and the corresponding cells cultured. Things (ie, cultured cells). Cultured cells include cells in primary culture and cells in subculture.
- AR42J cells are cancer cells, they cannot be used in regenerative medicine from the viewpoint of safety, even if their ability to produce insulin is increased.
- a technique for increasing the ability of non-tumor cells derived from the knee to produce and secrete insulin has been established, so that a large number of cells usable for regenerative medicine can be prepared.
- Conophylline can be isolated and purified from the leaves of Ervatamia microphylla, a plant belonging to the family Pseudocytaceae, as described in Production Example 1 (Umezawa, K. et al. Anticancer Res. 14: 2413-2418 (1994)). Modified method). From about 4 kg of leaves of Ervatamia microphylla, about 500 mg of conophylline crystals can be obtained.
- Conophorin and paticiffin can be produced by the method described in Kam TS, Anuradha S. Alkaloids from Tabernaeraontana divaricata. Photochemistry (1995) 40: 313-6.
- Non-tumor cells derived from the knee may be derived from mammals, and examples of mammals include primates such as humans and monkeys, and non-primates such as pigs, dogs, dogs, and rats. Can be.
- the cells may be from a healthy individual or from a patient in need of treatment. Patients are not limited to humans and may be non-healthy non-human animals.
- the individual is preferably a fetus or a newborn (for example, in the case of a pig, a pupa within 3 days after birth).
- the non-tumor cells may be exocrine cells or endocrine cells, but are preferably endocrine cells. Among endocrine cells, ⁇ cells and progenitor cells are more preferable.
- spleen-derived non-tumor cells can be induced to differentiate by culturing the non-tumor cells derived from the knee in the presence of the bin-powered alloid or its salt.
- non-tumor cells derived from the kidney can be induced to differentiate into insulin-producing and releasing cells (eg, ⁇ cells). Alternatively, it can increase the insulin production and / or secretion capacity of normal knee cells.
- culturing non-tumor cells derived from the knee in the presence of a bin alkaloid or a salt thereof allows isolation and purification of insulin from a culture (cultured cells or culture solution) by a known method. Can be.
- Insulin production and ⁇ or secretion capacity by culturing in the presence of a bottle force Al force Lloyd or its salt is increased, non-tumor cells from spleen, per medium lml 2. 5 10 at five concentrations 7-35 When cultured for one day, it can produce 10 ng or more, preferably 25 ng, more preferably 55 ng or more insulin in lm1 of the medium.
- Binary Aloyloid and its pharmacologically acceptable salts may be formulated into tablets, capsules, granules, powders, syrups, etc. and administered orally, or injected, suppositories, etc. It can also be formulated and administered parenterally by intraperitoneal or intravenous injection.
- the content of the bin alkaloid or its pharmacologically acceptable salt (active ingredient) in the preparation can be varied between 1 and 90% by weight.
- the active ingredient in the case of tablets, capsules, granules, powders and the like, it is preferable to contain the active ingredient in an amount of 5 to 80% by weight.
- the active ingredient is preferably contained in an amount of 1 to 30% by weight.
- parenterally administered injections it is preferable to contain 1 to 10% by weight of the active ingredient.
- FBS Fetal bovine serum
- a-guinea pig-Cyanin3 antibody Jackson Immuno Research Laboratories, inc. (West Grove, PA)
- Newborn piglets within 72 hours of age were obtained from (Takayama) pig farm. Immediately after transport to the operating room, all knees (abdominal and dorsal knees) were removed under general anesthesia. After removing connective tissue and attached blood around the excised knee, transfer it to a 10 ml beaker and place it in ophthalmic scissors. And shredded. The minced knee tissue pieces were transferred to 100 ml Erlenmeyer flasks, 50- 6 0 ml phosphate buffer of (PBS) was added, after rotating for 3 minutes at 110 rpm at low rotational stirrer, standing supernatant Was thrown away.
- PBS phosphate buffer of
- FIG. 2 shows the results of Experimental Example I.
- Ucotinamide (Akiyama, T. et al., Proc. Natl. Acad. Sci. USA 98: 48-53 (2001))
- HGF (Ocana, AG et al., J. Biol. Chem. 275: 1226-1232 (2000)) It has been reported in a limited experimental system to promote the differentiation of insulin-producing cells, but its effect is weak. As shown in Fig.
- Figure 3 shows the results of Experimental Example II. As shown in FIG. 3, if HGF or conophylline is added to nicotinamide after 8 to 20 days of culture, some insulin can be found in the medium. In addition, the combination of nicotinamide, HGF, and connobuline significantly increased the amount of insulin released as compared to other combinations or alone.
- AR42J-B13 cells Provided by Dr. Itaru Kojima of the bioregulatory cell field, Gunma University School of Medicine), which is a subclone of the AR42J with good HGF sensitivity, together with 20 ml of the culture solution supplemented with 10% FBS at 37 ° C , they were cultured in 5% C0 2 incubator scratch.
- one well of cells differentiated with 2 nM of activin A and 100 pM of HGF was prepared, and stored without the primary antibody in order to compare the effect of nonspecific binding of the secondary antibody.
- the slide glass was transferred to a container, and washed with PBS for fluorescent antibody 3 times for 5 minutes while shaking on a shaker.
- Hoechst33258 to the a-guinea pig-cyanin3 antibody diluted 100-fold with the blocking solution diluted 10-fold so as to make it 100-fold diluted, and place it in the same manner as the primary antibody.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/556,309 US20070232533A1 (en) | 2003-05-09 | 2004-05-10 | Use of Vinca Alkaloids and Salts Thereof |
JP2005506053A JP4696303B2 (ja) | 2003-05-09 | 2004-05-10 | ビンカアルカロイドおよびその塩の利用 |
EP04732040A EP1623986A4 (en) | 2003-05-09 | 2004-05-10 | USE OF A ALKALOID OF THE PERVENCHE AND ITS SALT |
US12/477,333 US8394629B2 (en) | 2003-05-09 | 2009-06-03 | Use of vinca alkaloids and salts thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-131256 | 2003-05-09 | ||
JP2003131256 | 2003-05-09 | ||
JP2003373665 | 2003-10-31 | ||
JP2003-373665 | 2003-10-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/477,333 Division US8394629B2 (en) | 2003-05-09 | 2009-06-03 | Use of vinca alkaloids and salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004099215A1 true WO2004099215A1 (ja) | 2004-11-18 |
Family
ID=33436426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006567 WO2004099215A1 (ja) | 2003-05-09 | 2004-05-10 | ビンカアルカロイドおよびその塩の利用 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20070232533A1 (ja) |
EP (1) | EP1623986A4 (ja) |
JP (1) | JP4696303B2 (ja) |
WO (1) | WO2004099215A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007102467A1 (ja) * | 2006-03-07 | 2007-09-13 | Keio University | コノフィリン及び/又はコノフィリジンの水溶液 |
JP2010533139A (ja) * | 2007-07-11 | 2010-10-21 | ピエール、ファーブル、メディカマン | 水溶性ビンフルニン塩を含んでなる安定な医薬組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160122762A1 (en) * | 2014-10-27 | 2016-05-05 | University Of Iowa Research Foundation | Methods of treating atherosclerosis |
CN115073481B (zh) * | 2021-03-13 | 2024-04-12 | 中国科学院昆明植物研究所 | 一种呋喃白坚木碱二聚体或其药学上可接受的盐及其制备方法和应用、药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003113111A (ja) * | 2001-10-02 | 2003-04-18 | Kyowa Hakko Kogyo Co Ltd | 糖尿病治療用医薬 |
JP2004121165A (ja) * | 2002-10-07 | 2004-04-22 | Asahi Kasei Corp | 膵幹様細胞の分化誘導方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11322602A (ja) | 1998-05-13 | 1999-11-24 | Kazuo Umezawa | 転写因子NFκB活性化阻害剤 |
US6159443A (en) | 1999-04-29 | 2000-12-12 | Vanderbilt University | X-ray guided drug delivery |
-
2004
- 2004-05-10 EP EP04732040A patent/EP1623986A4/en not_active Withdrawn
- 2004-05-10 US US10/556,309 patent/US20070232533A1/en not_active Abandoned
- 2004-05-10 WO PCT/JP2004/006567 patent/WO2004099215A1/ja active Application Filing
- 2004-05-10 JP JP2005506053A patent/JP4696303B2/ja not_active Expired - Fee Related
-
2009
- 2009-06-03 US US12/477,333 patent/US8394629B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003113111A (ja) * | 2001-10-02 | 2003-04-18 | Kyowa Hakko Kogyo Co Ltd | 糖尿病治療用医薬 |
JP2004121165A (ja) * | 2002-10-07 | 2004-04-22 | Asahi Kasei Corp | 膵幹様細胞の分化誘導方法 |
Non-Patent Citations (3)
Title |
---|
GARCIA-OCANA A. ET AL.: "Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 2, 14 January 2000 (2000-01-14), pages 1226 - 1232, XP002944870 * |
KAM T.-S. ET AL.: "Biologically active indole and bisindole alkaloids from Tabernaemontana divaricata", ORG. BIOMOL. CHEM., vol. 1, no. 8, 21 April 2003 (2003-04-21), pages 1292 - 1297, XP002980999 * |
WATANABE T. ET AL.: "Pancreatic beta-cell replication and amelioration of surgical diabetes by Reg protein", PROC. NATL. ACAD. SCI., vol. 91, April 1994 (1994-04-01), pages 3589 - 3592, XP002944867 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007102467A1 (ja) * | 2006-03-07 | 2007-09-13 | Keio University | コノフィリン及び/又はコノフィリジンの水溶液 |
US8178135B2 (en) | 2006-03-07 | 2012-05-15 | Keio University | Aqueous solution of conophylline and/or conophyllidine |
JP2010533139A (ja) * | 2007-07-11 | 2010-10-21 | ピエール、ファーブル、メディカマン | 水溶性ビンフルニン塩を含んでなる安定な医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP1623986A1 (en) | 2006-02-08 |
US20090239301A1 (en) | 2009-09-24 |
JP4696303B2 (ja) | 2011-06-08 |
US8394629B2 (en) | 2013-03-12 |
EP1623986A4 (en) | 2008-04-02 |
US20070232533A1 (en) | 2007-10-04 |
JPWO2004099215A1 (ja) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7339296B2 (ja) | ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長 | |
WO2014157918A1 (ko) | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 | |
JP2009520470A (ja) | 新規の乳酸桿菌株及びその使用 | |
KR20140003631A (ko) | 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도 | |
WO2021137600A1 (ko) | 락토바실러스 퍼멘텀 균주 및 이를 포함하는 대사질환의 예방 또는 치료용 조성물 | |
JP2009510053A (ja) | 桂皮抽出物を有効成分として含む腸内菌叢改善及び免疫機能増進用組成物 | |
US8394629B2 (en) | Use of vinca alkaloids and salts thereof | |
Xie et al. | Scorpion in combination with Gypsum: novel antidiabetic activities in streptozotocin-induced diabetic mice by up-regulating pancreatic PPARγ and PDX-1 expressions | |
KR100866008B1 (ko) | 대사성 골질환의 예방 치료약 | |
Chao et al. | A novel human stem cell coculture system that maintains the survival and function of culture islet-like cell clusters | |
WO2015076430A1 (ko) | 메트포민을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
Divakaran et al. | Sesaminol induces brown and beige adipocyte formation through suppression of myogenic program | |
WO2023027317A1 (ko) | 편도 중간엽 줄기세포 유래 엑소좀을 포함하는 근육 감소 관련 질환 치료용 조성물 | |
WO2013015611A2 (ko) | 효모 가수분해물을 유효성분으로 포함하는 연골세포 손상방지 및 재생효과를 갖는 조성물 | |
Amoli et al. | Curcumin inhibits in vitro MCP-1 release from mouse pancreatic islets | |
KR20210058723A (ko) | 비멘틴 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
WO2011037416A2 (ko) | 세포이식술을 위한 혼합세포복합체인 세포스페로이드의 제조방법 및 이의 이용방법 | |
WO2023075346A1 (ko) | 항산화 기전 조절을 통한 자연살해세포의 항암 기능 향상 | |
WO2011102577A1 (ko) | 스코폴린 및 그의 유도체의 신규 용도 | |
WO2019216465A1 (en) | Composition for prevention of breast cancer comprising cyclic dipeptide and methods of preparation thereof | |
AU757489B2 (en) | Method for inhibiting cytokine production by cells | |
KR101581508B1 (ko) | 코엔자임 q10을 유효성분으로 포함하는 염증성 질환 또는 면역거부질환의 예방 또는 치료용 조성물 | |
Elzawahry et al. | The role of stem cells and vitamin D in the attenuation of liver and kidney functions in STZ-induced diabetic rats: Biochemical study | |
WO2022055238A1 (ko) | 경막외 지방 중간엽 줄기세포 유래 엑소좀을 포함하는 골 질환 치료용 조성물 | |
WO2022220478A1 (ko) | 신규한 sd911 화합물을 유효성분으로 포함하는 이식 거부 반응의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506053 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004732040 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048160594 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004732040 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10556309 Country of ref document: US Ref document number: 2007232533 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10556309 Country of ref document: US |